摘要
目的:观察异甘草酸镁对原发性肝癌介入治疗术后肝功能指标的影响。方法:将74例原发性肝癌患者介入治疗后随机分成治疗组(37例)和对照组(37例),对照组采用硫普罗宁常规护肝治疗,治疗组应用异甘草酸镁治疗。比较两组之间在丙氨酸氨基转移(ALT)、凝血酶原时间(PT)、总胆红素(TBIL)、肝促凝血活酶试验(HPT)指标及相关安全性指标方面有无差异。结果:治疗组术后10d ALT、TBIL、PT、HPT与对照组比较均有统计学差异,未发现与异甘草酸镁有关的药物过敏、心悸、头晕、皮疹等不良反应。结论:异甘草酸镁在治疗介入术后肝损伤方面疗效确切,比较安全,适合临床广泛应用。
Objective：To observe the effect of magnesium isoglycyrrhizinate on liver function in patients with primary liver cancer after interventional treatment. Methods：All 74 patients with primary liver cancer after interventional therapy were randomly divided into treatment group （37 cases） and control group （37 cases）. The control group was given routine therapy （mainly tiopronin） , the treatment group received magnesium isoglycyrrhizinate. Compared alanine aminotransferase （ ALT）, prothrombin time （ PT）, total bilirubin （ TBIL）, hepatic pro - thromboplastin test （HPT） of livers between two groups. Results：There were statistically significance in the ALT, TBIL, PT and HPT between treatment group and control group after ten days. It was not found that drug allergies, heart palpitations, dizziness, skin rashes and other adverse reactions induced by magnesium isoglycyrrhizinate. Conclusion：The efficacy of magnesium isoglycyrrhizinate on liver injury after interventional treatment is relatively safe and could be widespread clinical application.
出处
《现代肿瘤医学》
CAS
2016年第9期1421-1423,共3页
Journal of Modern Oncology
关键词
异甘草酸镁
原发性肝癌
介入治疗
magnesium isoglycyrrhizinate, primary liver cancer, intmwention therapy
作者简介
辛文娟（1972-），女，河北邢台人，主治医师，主要从事内科工作。E—mail：xinwenjuan2014@163．com
